^
No biomarker
Astrocytoma
everolimus
Sensitive: A1 - Approval
No biomarker
Astrocytoma
carmustine
Sensitive: A1 - Approval
No biomarker
Anaplastic Astrocytoma
temozolomide
Sensitive: A1 - Approval
No biomarker
Anaplastic Astrocytoma
PCV
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
No biomarker
Astrocytoma
lomustine + procarbazine hydrochloride + vincristine liposomal
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
No biomarker
Astrocytoma
temozolomide gel
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
trametinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
dabrafenib
Sensitive: A2 - Guideline
IDH1 R132H
Anaplastic Astrocytoma
temozolomide
Sensitive: B - Late Trials
MGMT promoter methylation
Anaplastic Astrocytoma
temozolomide
Sensitive: B - Late Trials
BRAF V600
Astrocytoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Anaplastic Astrocytoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Astrocytoma
dabrafenib
Sensitive: C1 - Off-label
IDH1 mutation
Astrocytoma
temozolomide
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Astrocytoma
selumetinib
Sensitive: C2 – Inclusion Criteria
KIAA1549-BRAF fusion
Astrocytoma
selumetinib
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Anaplastic Astrocytoma
atezolizumab + cobimetinib
Sensitive: C3 – Early Trials
IDH2 mutation
Anaplastic Astrocytoma
PCV
Sensitive: C3 – Early Trials
IDH1 mutation
Anaplastic Astrocytoma
PCV
Sensitive: C3 – Early Trials
ABCB1 G412G
Anaplastic Astrocytoma
temozolomide
Sensitive: C3 – Early Trials
TMB-H
Anaplastic Astrocytoma
nivolumab
Sensitive: C3 – Early Trials
NACC2-NTRK2 fusion
Anaplastic Astrocytoma
larotrectinib
Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion
Astrocytoma
ABSK-091
Sensitive: C4 – Case Studies
BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion
Astrocytoma
larotrectinib
Sensitive: C4 – Case Studies
IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation
Anaplastic Astrocytoma
carboplatin + temozolomide + vincristine
Resistant: C4 – Case Studies
BRAF V600E + PIK3CA mutation
Astrocytoma
vemurafenib + everolimus
Sensitive: C4 – Case Studies
BRAF mutation
Anaplastic Astrocytoma
dabrafenib
Sensitive: C4 – Case Studies
BRAF V600E
Astrocytoma
palbociclib + PLX4720
Sensitive: D – Preclinical
BRAF V600E
Astrocytoma
palbociclib
Sensitive: D – Preclinical
BRAF V600E
Astrocytoma
PLX4720
Sensitive: D – Preclinical